Search research articles
Contact Us
Filters
Showing results (31-40 of 101) with videos related to
Page
of 11
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Should Changes in Drug Price Over Time be Considered in Cost-Effectiveness Analyses?
A Millier, B Briquet, S Aballea, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Public Beliefs and Attitudes about Schizophrenia, Major Depression and Psychotropic Medication in Tunisia
T Refaï, A Millier, C Rémuzat, et al.
Pharmacopsychiatry
|
June 14, 2003
Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment
W Löffler, R Kilian, M Toumi, et al.
Acta Psychiatrica Scandinavica
|
July 6, 2004
Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics
R Kilian, S Dietrich, M Toumi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
An Overview of the Biosimilar Market in the Us
K E Young, C Rémuzat, D Urbinati, et al.
L'Encephale
|
June 12, 1998
[Cost of illness: an inextricable maze or an aid in decision making? The case of schizophrenia]
R Launois, M Toumi, J Reboul-Marty, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
|
November 24, 2004
Infrared and polarized Raman spectra of a noncentrosymmetric compound "sodium samarium fluorosilicate" NaSmSiO4.0.25NaF
A Dakhlaoui, M Toumi, L S Smiri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Boosting Biosimilars Uptake in European Countries
K E Young, C Rémuzat, D Urbinati, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Access To Orphan Drugs in France: The Case Of Siklos For The Treatment of Sickle Cell Syndrome Before The Council of State
S Murteira, Hammi E El, A Kornfeld, et al.
Acta Psychiatrica Scandinavica
|
October 7, 2006
The impact of caregivers' characteristics, patients' conditions and regional differences on family burden in schizophrenia: a longitudinal analysis
C Roick, D Heider, M Toumi, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 101) with videos related to
Sort By:
Page
of 11
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Should Changes in Drug Price Over Time be Considered in Cost-Effectiveness Analyses?
A Millier, B Briquet, S Aballea, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Public Beliefs and Attitudes about Schizophrenia, Major Depression and Psychotropic Medication in Tunisia
T Refaï, A Millier, C Rémuzat, et al.
Pharmacopsychiatry
|
June 14, 2003
Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment
W Löffler, R Kilian, M Toumi, et al.
Acta Psychiatrica Scandinavica
|
July 6, 2004
Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics
R Kilian, S Dietrich, M Toumi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
An Overview of the Biosimilar Market in the Us
K E Young, C Rémuzat, D Urbinati, et al.
L'Encephale
|
June 12, 1998
[Cost of illness: an inextricable maze or an aid in decision making? The case of schizophrenia]
R Launois, M Toumi, J Reboul-Marty, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
|
November 24, 2004
Infrared and polarized Raman spectra of a noncentrosymmetric compound "sodium samarium fluorosilicate" NaSmSiO4.0.25NaF
A Dakhlaoui, M Toumi, L S Smiri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Boosting Biosimilars Uptake in European Countries
K E Young, C Rémuzat, D Urbinati, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Access To Orphan Drugs in France: The Case Of Siklos For The Treatment of Sickle Cell Syndrome Before The Council of State
S Murteira, Hammi E El, A Kornfeld, et al.
Acta Psychiatrica Scandinavica
|
October 7, 2006
The impact of caregivers' characteristics, patients' conditions and regional differences on family burden in schizophrenia: a longitudinal analysis
C Roick, D Heider, M Toumi, et al.
Page
of 11